![Ingrid Delaet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ingrid Delaet
General Counsel bei
NEUROCRINE BIOSCIENCES, INC.
Vermögen: 3 Mio $ am 31.08.2026
Profil
Dr. Ingrid Delaet is a Chief Regulatory Officer at Neurocrine Biosciences, Inc. Dr. Delaet was previously employed as a Senior Vice President-Regulatory Affairs by Intercept Pharmaceuticals, Inc., a Global Regulatory Affairs by Bristol Myers Squibb Co., a Head-Clinical Research by CellPro, Inc., and a Head-Clinical Research by Wyeth-Ayerst Research.
She received her graduate degree from Université Libre de Bruxelles and a doctorate degree from Université Libre de Bruxelles.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.09.2026 | 18 289 ( 0,02 % ) | 3 Mio $ | 31.08.2026 |
Aktive Positionen von Ingrid Delaet
| Unternehmen | Position | Beginn |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | General Counsel | 01.01.2021 |
Ehemalige bekannte Positionen von Ingrid Delaet
| Unternehmen | Position | Ende |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | General Counsel | 01.01.2021 |
| BRISTOL-MYERS SQUIBB COMPANY | General Counsel | 01.09.2016 |
Wyeth-Ayerst Research | Corporate Officer/Principal | - |
CellPro, Inc.
 CellPro, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Corporate Officer/Principal | - |
Ausbildung von Ingrid Delaet
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
59
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Neurocrine Biosciences, Inc.
 Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
CellPro, Inc.
CellPro, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Université Libre de Bruxelles
 Université Libre de Bruxelles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wyeth-Ayerst Research |
